Rubella (German Measles) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Rubella (German Measles) - Pipeline Review, H2 2016

Rubella (German Measles) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Rubella (German Measles) - Pipeline Review, H2 2016
Published Nov 16, 2016
45 pages — Published Nov 16, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) Pipeline Review, H2 2016, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape.

Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 2, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Rubella (German Measles).

Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipelin

  
Source:
Document ID
GMDHC8643IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Rubella (German Measles) Overview61
Therapeutics Development72
  Pipeline Products for Rubella (German Measles) Overview71
  Pipeline Products for Rubella (German Measles) Comparative Analysis81
Rubella (German Measles) Therapeutics under Development by Companies91
Rubella (German Measles) Therapeutics under Investigation by Universities/Institutes101
Rubella (German Measles) Pipeline Products Glance114
  Late Stage Products111
  Clinical Stage Products121
  Early Stage Products131
  Unknown Stage Products141
Rubella (German Measles) Products under Development by Companies151
Rubella (German Measles) Products under Investigation by Universities/Institutes161
Rubella (German Measles) Companies Involved in Therapeutics Development179
  Beijing Minhai Biotechnology Co., Ltd171
  Beijing Tiantan Biological Products Co., Ltd.181
  Biological E. Limited191
  Daiichi Sankyo Company, Limited201
  GlaxoSmithKline Plc211
  Indian Immunologicals Limited221
  Prometheon Pharma, LLC231
  Sinovac Biotech Ltd.241
  Zydus Cadila Healthcare Limited251
Rubella (German Measles) Therapeutics Assessment266
  Assessment by Monotherapy Products261
  Assessment by Combination Products271
  Assessment by Route of Administration282
  Assessment by Molecule Type302
Drug Profiles3211
  (measles + mumps + rubella + varicella) vaccine Drug Profile321
  (measles + mumps + rubella + varicella) vaccine Drug Profile331
  (measles + mumps + rubella) vaccine Drug Profile341
  (measles + mumps + rubella) vaccine Drug Profile351
  (measles + mumps + rubella) vaccine Drug Profile361
  (measles + rubella + varicella) vaccine Drug Profile371
  (measles + rubella) vaccine Drug Profile381
  (measles + rubella) vaccine Drug Profile391
  (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine Drug Profile401
  rubella vaccine Drug Profile411
  VN-0102 Drug Profile421
Rubella (German Measles) Dormant Projects431
Appendix442
  Methodology441
  Coverage441
  Secondary Research441
  Primary Research441
  Expert Panel Validation441
  Contact Us441
  Disclaimer451

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Rubella (German Measles) - Pipeline Review, H2 2016" Nov 16, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rubella-German-Measles-Pipeline-Review-H2-2016-2088-16810>
  
APA:
Global Markets Direct - Market Research. (2016). Rubella (German Measles) - Pipeline Review, H2 2016 Nov 16, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rubella-German-Measles-Pipeline-Review-H2-2016-2088-16810>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.